Effect of Empagliflozin on Ventricular Repolarization.

Sponsor
University of Sao Paulo
Study ID
NCT04117763
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The present project aims to investigate if the empagliflozin has an antiarrhythmic action. Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease, the investigators will verify if empagliflozin is associated with a reduction in electrical instability.

Key Dates

Start date
Oct 4, 2019
Status verified
May 2024
Primary completion
Mar 31, 2024
Completion
Mar 31, 2024

Study Design

Enrollment
90 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Empagliflozin
    Empagliflozin 25 mg once daily for 3 months

Primary Outcome Measure

Arrhythmogenic burden [ Time Frame: 3 months ]

Related Studies